New data from Eli Lilly shows that its drug Zepbound (tirzepatide), originally designed to treat obesity as a GLP‑1 agonist, can also reduce the symptoms of psoriatic arthritis when given in addition to existing immunotherapy. According to the results report, combining Zepbound with an immunological drug led to an improvement in psoriatic arthritis symptoms compared to standard immunological therapy alone. The article states that this is an additional benefit "on top" of already established immune-targeting treatments, not a replacement for them. Zepbound belongs to the so-called GLP‑1 drugs that are commonly used in obesity and type 2 diabetes, and this new data set expands the possible areas of its use. However, the text does not give specific percentages of improvement, study size, or exact statistical results. The main fact of the article is that in the data presented, a reduction in the symptoms of psoriatic arthritis was observed after adding Zepbound to the immunological drug.